Einzeltreffer — DigiBib

The efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) is unclear. This study aimed to evaluate the efficacy of second-line chemotherapy in patients with pulmonary LCNEC. We retrospectively reviewed patients with pulmonary LCNEC or possible LCNEC (pLCNEC) who received platinum-based chemotherapy as the first-line treatment. Among these patients, we evaluated the efficacy of second-line treatment by comparing patients with small cell lung cancer (SCLC group). Of the 61 patients with LCNEC or pLCNEC (LCNEC group) who received first-line chemotherapy, 39 patients were treated with second-line chemotherapy. Among the 39 patients, 61.5% received amrubicin monotherapy. The median progression-free survival (PFS) and overall survival (OS) in the LCNEC groups were 3.3 and 8.3 months, respectively. No significant differences in the PFS (hazard ratio [HR]: 0.924, 95% confidence interval [CI] 0.647-1.320; P = 0.664) and OS (HR: 0.926; 95% CI 0.648-1.321; P = 0.670) were observed between the LCNEC and SCLC groups. In patients treated with amrubicin, the PFS (P = 0.964) and OS (P = 0.544) were not different between both the groups. Second-line chemotherapy, including amrubicin, may be considered as a treatment option for patients with pulmonary LCNEC.

Titel:	Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Autor/in / Beteiligte Person:	Iida, Y ; Wakuda, K ; Kenmotsu, H ; Doshita, K ; Kodama, H ; Nishioka, N ; Miyawaki, E ; Miyawaki, T ; Mamesaya, N ; Kobayashi, H ; Omori, S ; Ko, R ; Ono, A ; Naito, T ; Murakami, H ; Sugino, T ; Gon, Y ; Takahashi, T
Link:	Full Text Finder (Volltext)
Zeitschrift:	Scientific reports, Jg. 14 (2024-04-01), Heft 1, S. 7641
Veröffentlichung:	London : Nature Publishing Group, copyright 2011-, 2024
Medientyp:	academicJournal
ISSN:	2045-2322 (electronic)
DOI:	10.1038/s41598-024-58327-w
Schlagwort:	Humans Retrospective Studies Anthracyclines therapeutic use Lung Neoplasms pathology Small Cell Lung Carcinoma pathology Carcinoma, Large Cell drug therapy Carcinoma, Large Cell pathology Carcinoma, Neuroendocrine pathology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Sci Rep] 2024 Apr 01; Vol. 14 (1), pp. 7641. <i>Date of Electronic Publication: </i>2024 Apr 01. MeSH Terms: Lung Neoplasms* / pathology ; Small Cell Lung Carcinoma* / pathology ; Carcinoma, Large Cell* / drug therapy ; Carcinoma, Large Cell* / pathology ; Carcinoma, Neuroendocrine* / pathology ; Humans ; Retrospective Studies ; Anthracyclines / therapeutic use References: Clin Lung Cancer. 2003 Jan;4(4):224-8. (PMID: 14624710) ; J Thorac Oncol. 2009 Sep;4(9):1049-59. (PMID: 19652623) ; Ann Oncol. 2013 Jun;24(6):1548-52. (PMID: 23406729) ; Lung Cancer. 2012 Mar;75(3):368-73. (PMID: 21920624) ; J Clin Oncol. 2005 Dec 1;23(34):8774-85. (PMID: 16314638) ; Clin Lung Cancer. 2016 Sep;17(5):e121-e129. (PMID: 26898325) ; J Thorac Oncol. 2013 Jul;8(7):980-4. (PMID: 23774385) ; J Clin Oncol. 2006 Dec 1;24(34):5441-7. (PMID: 17135646) ; Lancet Respir Med. 2020 Jul;8(7):726-737. (PMID: 32649920) ; Jpn J Clin Oncol. 2011 Jul;41(7):897-901. (PMID: 21636606) ; J Clin Oncol. 2007 May 20;25(15):2086-92. (PMID: 17513814) ; Lancet Oncol. 2020 Sep;21(9):1224-1233. (PMID: 32888454) ; Eur Respir J. 2017 Jun 1;49(6):. (PMID: 28572122) ; J Clin Oncol. 2008 Nov 20;26(33):5401-6. (PMID: 18854562) ; J Thorac Cardiovasc Surg. 2002 Aug;124(2):285-92. (PMID: 12167788) ; J Clin Oncol. 2022 Feb 20;40(6):671-680. (PMID: 34985925) ; Bone Marrow Transplant. 2013 Mar;48(3):452-8. (PMID: 23208313) ; J Clin Oncol. 1999 Feb;17(2):658-67. (PMID: 10080612) ; Am J Respir Crit Care Med. 2021 Jun 1;203(11):1343-1352. (PMID: 33835899) ; Lung Cancer. 2014 Apr;84(1):67-72. (PMID: 24530204) ; Mol Clin Oncol. 2017 May;6(5):718-722. (PMID: 28529747) ; Lung Cancer. 2012 Aug;77(2):365-70. (PMID: 22579297) ; J Clin Oncol. 2014 Dec 10;32(35):4012-9. (PMID: 25385727) ; J Thorac Oncol. 2011 Feb;6(2):244-85. (PMID: 21252716) ; J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. (PMID: 10655437) ; J Clin Oncol. 2015 Oct 20;33(30):3488-515. (PMID: 26324367) ; Sci Rep. 2016 Jan 11;6:18999. (PMID: 26750506) ; Int J Clin Oncol. 2014 Feb;19(1):63-7. (PMID: 23250620) ; J Thorac Oncol. 2016 Jan;11(1):39-51. (PMID: 26762738) ; J Clin Oncol. 2006 Dec 1;24(34):5448-53. (PMID: 17135647) ; J Thorac Oncol. 2015 Sep;10(9):1240-1242. (PMID: 26291007) Substance Nomenclature: 93N13LB4Z2 (amrubicin) ; 0 (Anthracyclines) Entry Date(s): Date Created: 20240401 Date Completed: 20240403 Latest Revision: 20240404 Update Code: 20240404 PubMed Central ID: PMC10984918

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.